Arrowhead Research Stock News

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been given a consensus rating of Buy by the thirteen research firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price target among analysts that []

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 17, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that its collaborator, Janssen Pharmaceuticals, Inc. , (Janssen) one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has disclosed its collaboration with Arrowhead on

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection at AASLD Liver Meeting

Prudential Financial Inc. trimmed its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 5.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 65,031 shares of the biotechnology companys stock after selling 4,055 shares during the period. Prudential Financial Inc. owned 0.06% []

Arrowhead shares still have over 33% near-term upside as upcoming Janssen JNJ-3989 news is set to be released in mid-November. Arrowhead's latest bump in the road in ARO-EnaC will soon be forgotten if

Arrowhead Pharmaceuticals is a leading innovator in promising drugs to treat crippling diseases. This piece focuses on its two most advanced liver disease drugs in trial, which also form the practical

With the trading day more than halfway over, the broad markets were somewhat mixed.

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2021 Results - Earnings Call Transcript

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 123.08% year over year to ($0.

This biotech underdog offers more than meets the eye.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss fiscal 2021 third quarter results

The stock price of Arrowhead, a biopharmaceutical company that develops RNA interference therapies, has seen a large 30% fall over the last five trading days. The decline came after the company decide

Arrowhead's stock dropped 25% on preliminary update from ongoing chronic toxicology study in rats causing voluntary pause. However, further safety data released later on could possibly reverse this. W

The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) tied to the ARO-EnAC phase 1/2 study halt is overdone, leading H.C. Wainwright & Co. to reiterate its Buy rating.

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced interim results from the first two cohorts of Phase 1b study of ARO-HIF2 for clear cell renal cell carcinoma (ccRCC).  ARO-HIF2 is the fi